07.10.2025 09:30 Rita Longobardi
HemostOD, a Swiss company developing donor-free human blood platelets, has secured CHF 4.3 million in seed-extension funding to accelerate its pre-IND development and establish commercial-scale production capabilities.
HemostOD is working on a platform that enables the ex vivo production of universal, off-the-shelf human blood platelets, addressing the global need for reliable and safe platelet supply. With the newly secured CHF 4.3 million, the company will move closer to regulatory readiness while proving the scalability of its manufacturing process.
The financing will allow HemostOD to launch a commercial-scale pilot production line, demonstrating that its platelet manufacturing technology can be translated from laboratory scale to industrial application. In parallel, the company plans to hold a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). These steps will enable the company to validate its approach on a larger scale and align with regulatory requirements for future clinical development.
The Biotech startup has won Venture Kick and participated in Venture Leaders Biotech. “With the support of Venture Kick and Venturelab, we improved our pitch and strengthened our interactions with investors,” highlighted Co-Founder and CEO Faouzi Khechana.
HemostOD's CEO (Faouzi Khechana), CSO (Nicoletta Sorvillo), and CTO (Elodie Dahan)
